Compare CIX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | EVMN |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.0M | 405.2M |
| IPO Year | 1997 | 2025 |
| Metric | CIX | EVMN |
|---|---|---|
| Price | $37.12 | $13.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | 7.2K | ★ 342.2K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | ★ 9.48% | N/A |
| EPS Growth | 17.04 | ★ 75.23 |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $158,285,000.00 | $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | 8.46 | ★ 85.71 |
| 52 Week Low | $20.29 | $10.47 |
| 52 Week High | $36.25 | $33.20 |
| Indicator | CIX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 80.67 | 48.50 |
| Support Level | $23.25 | $12.07 |
| Resistance Level | N/A | $15.06 |
| Average True Range (ATR) | 1.66 | 0.75 |
| MACD | 0.39 | -0.10 |
| Stochastic Oscillator | 99.94 | 40.44 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.